358 F. Supp. 3d 389
D.N.J.2018Background
- Takeda owns four patents covering Prevacid SoluTab (lansoprazole ODT). Zydus submitted an ANDA (generic) and later an amended ANDA with minor excipient changes plus a Paragraph IV certification asserting noninfringement.
- In prior litigation, the Federal Circuit construed the '994 patent term "fine granules" as "precisely 400 µm or less," and held Zydus’s earlier ANDA (412.28 µm) did not literally infringe.
- Takeda sued Zydus in 2018 based on the amended ANDA; Zydus asserted antitrust counterclaims (Sherman Act and New Jersey Antitrust Act) alleging Takeda filed sham litigation to delay FDA approval.
- Takeda moved to dismiss the antitrust counterclaims under Rule 12(b)(6), invoking Noerr-Pennington petitioning immunity, arguing filing suit in response to a Paragraph IV certification is per se reasonable.
- Zydus alleges Takeda ignored Zydus’s detailed noninfringement explanations and offers to share the amended ANDA, and that FDA had indicated tentative approval before Takeda’s suit—supporting sham-litigation and causation allegations.
- The Court denied the motion to dismiss, finding Zydus’s pleadings sufficiently alleged objective and subjective baselessness (sham) and an antitrust causal link at the pleading stage; determination of Noerr immunity and causation requires a developed factual record.
Issues
| Issue | Plaintiff's Argument (Takeda) | Defendant's Argument (Zydus) | Held |
|---|---|---|---|
| Whether Noerr-Pennington immunizes Takeda's infringement suit | Filing in response to a Paragraph IV is per se reasonable; immunity applies | Takeda's suit is a sham: prior Federal Circuit ruling and Zydus's noninfringement submissions show objective and subjective baselessness | Denied — pleadings adequate to overcome immunity at dismissal stage; factual record required |
| Whether the suit was objectively baseless | Paragraph IV creates a statutory right to sue; reasonable basis existed | ANDA and letters show noninfringement; prior ruling establishes no literal infringement | Denied — court cannot resolve objective baselessness on present record |
| Whether Takeda acted with anticompetitive intent (subjective baselessness) | No improper intent; suit was legitimate enforcement | Takeda ignored Zydus's offers and noninfringement evidence, suggesting intent to delay competition | Denied — allegations suffice to plausibly infer anticompetitive intent |
| Whether Zydus plausibly pleaded causation/antitrust injury | Zydus lacked FDA approval after 2014 regardless, so Takeda’s suit did not cause injury | Zydus alleges FDA was prepared to approve the amended ANDA and would have, but for Takeda's suit | Denied — factual dispute; pleadings sufficiently allege a causal link at this stage |
Key Cases Cited
- Prof'l Real Estate Inv'rs, Inc. v. Columbia Pictures Indus., Inc., 508 U.S. 49 (Noerr-Pennington doctrine and sham-litigation exception)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading standard: plausible claim required)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standard and treating legal conclusions)
- Takeda Pharm. Co. v. Zydus Pharms. USA, Inc., 743 F.3d 1359 (Fed. Cir.) (prior claim construction: "precisely 400 µm or less")
- Hanover 3201 Realty, LLC v. Village Supermarkets, Inc., 806 F.3d 162 (3d Cir.) (Noerr-Pennington and petitioning immunity principles)
- In re Wellbutrin XL Antitrust Litig., 868 F.3d 132 (3d Cir.) (requirement to prove substantive antitrust violation and causation after rebutting Noerr immunity)
- In re Lipitor Antitrust Litig., 868 F.3d 231 (3d Cir.) (discussion of sham-litigation standards)
- Otsuka Pharm. Co. v. [opinion], 118 F. Supp. 3d 646 (D.N.J. 2015) (Paragraph IV does not automatically immunize patent-holder; sham litigation pleadings sufficient)